The Net Margin of Acceleron Pharma Inc (XLRN) is
-179.45%.
Net Margin measures the percentage of net income derived from total revenue after all expenses. It signals how much actual profit a company retains from its sales.
| Date |
Value |
| 2020-12-31 |
-179.45%
|
| 2019-12-31 |
-168.75%
|
| 2018-12-31 |
-849.68%
|
| 2017-12-31 |
-804.52%
|
| 2016-12-31 |
-205.29%
|
| 2015-12-31 |
-352.98%
|
| 2014-12-31 |
-350.38%
|
| 2013-12-31 |
-38.27%
|
| 2012-12-31 |
-213.64%
|
| 2011-12-31 |
44.83%
|
| Ticker |
Name |
Value |
|
ABBV
|
AbbVie Inc.
|
6.91%
|
|
ARNA
|
Arena Pharmaceuticals Inc
|
-1141542.60%
|
|
LEGN
|
Legend Biotech Corporation
|
-28.85%
|
|
RLAY
|
Relay Therapeutics, Inc.
|
-1800.58%
|
|
TGTX
|
TG Therapeutics, Inc.
|
72.56%
|
|
VRTX
|
Vertex Pharmaceuticals Incorporated
|
32.94%
|
|
AMGN
|
Amgen Inc
|
20.98%
|
|
ASND
|
Ascendis Pharma A/S
|
-31.67%
|
|
BPMC
|
Blueprint Medicines Corp
|
-13.19%
|
|
FGEN
|
FibroGen Inc
|
-160.63%
|
|
MRTX
|
Mirati Therapeutics Inc
|
-5955.55%
|
|
RVMD
|
Revolution Medicines, Inc.
|
-3768.28%
|
|
TPTX
|
Turning Point Therapeutics Inc
|
-767.30%
|
|
CCXI
|
Churchill Capital Corp XI
|
-408.87%
|
|
IONS
|
Ionis Pharmaceuticals, Inc.
|
-40.41%
|
|
IOVA
|
Iovance Biotherapeutics Inc
|
-148.38%
|
|
ALXO
|
ALX Oncology Holdings Inc
|
-3876.27%
|
|
GILD
|
Gilead Sciences, Inc.
|
28.90%
|
|
NTLA
|
Intellia Therapeutics, Inc.
|
-609.85%
|
|
SRPT
|
Sarepta Therapeutics, Inc.
|
-32.45%
|
|
VIE
|
Viela Bio Inc
|
-1293.07%
|
|
ALLO
|
Allogene Therapeutics, Inc.
|
-1170863.70%
|
|
APLS
|
Apellis Pharmaceuticals, Inc.
|
2.23%
|
|
BHVN
|
Biohaven Ltd.
|
-1205.09%
|
|
FATE
|
Fate Therapeutics Inc
|
-2051.08%
|
|
SWTX
|
SpringWorks Therapeutics, Inc.
|
-134.73%
|
|
950220.KQ
|
Neoimmunetech Inc
|
-33533.01%
|
|
CRSP
|
CRISPR Therapeutics AG
|
-16569.77%
|
|
MRNA
|
Moderna, Inc.
|
-145.16%
|
|
REGN
|
Regeneron Pharmaceuticals, Inc.
|
31.41%
|
|
950160.KQ
|
Kolon TissueGene Inc
|
-3733.25%
|
|
950200.KQ
|
Psomagen Inc
|
-5.04%
|
|
HALO
|
Halozyme Therapeutics, Inc.
|
22.69%
|
|
UTHR
|
United Therapeutics Corporation
|
41.94%
|